Concord Medical Regains Compliance with NYSE Minimum Price Requirement

Rhea-AI Summary

Concord Medical Services Holdings (NYSE: CCM), a Chinese healthcare provider specializing in cancer treatment, research, education, and prevention, has regained compliance with the New York Stock Exchange's (NYSE) minimum price requirement. The company received a Compliance Notice on August 6, 2024, confirming that it is no longer below the NYSE's continued listing criterion of a minimum average share price of US$1.00 over a 30 trading-day period.

This development follows a previous notification from the NYSE on February 12, 2024, which had informed Concord Medical that it was below compliance standards due to the trading price of its American Depositary Shares. With this latest update, Concord Medical has successfully addressed the compliance issue and is no longer considered below the NYSE Minimum Price Requirement.

Positive

• Regained compliance with NYSE minimum price requirement
• No longer at risk of delisting from NYSE due to share price

Negative

• None.

Financial Analyst

Concord Medical's compliance with NYSE listing requirements is a positive development for the company. Regaining compliance removes the immediate threat of delisting, which could have severely impacted investor confidence and the company's ability to raise capital. However, it's important to note that this doesn't necessarily reflect an improvement in the company's fundamental performance or financial health.

The stock's recovery to meet the $1 minimum price requirement could be due to various factors, including market sentiment, sector trends, or company-specific news. Investors should look beyond this compliance issue and focus on Concord Medical's operational performance, revenue growth and profitability metrics to gauge its long-term viability and investment potential in the competitive healthcare sector.

Market Research Analyst

This compliance news, while positive, should be viewed in the broader context of Concord Medical's market position. As a specialized cancer treatment provider in China, the company operates in a growing yet highly regulated market. The initial price decline that led to non-compliance might indicate underlying challenges or market skepticism about the company's growth prospects or financial stability.

Investors should consider:

• China's healthcare reforms and their impact on private providers
• Concord Medical's market share and competitive advantages
• The company's expansion plans and ability to capitalize on China's increasing demand for cancer treatment services

While regaining compliance is a step in the right direction, it's the company's ability to deliver sustainable growth and profitability that will ultimately drive long-term shareholder value.

BEIJING, Aug. 7, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it has received a letter from the New York Stock Exchange ("NYSE") dated August 6, 2024 (the "Compliance Notice"), notifying the Company that it is no longer considered below the NYSE's continued listing criterion of a minimum average share price of US$1.00 over a 30 trading-day period (the "NYSE Minimum Price Requirement").

As previously announced, the Company received a letter from the NYSE dated February 12, 2024, notifying the Company that it was below compliance standards due to the trading price of its American Depositary Shares. Following the receipt of the Compliance Notice, the Company is no longer considered below the NYSE Minimum Price Requirement, and has regained compliance regarding this matter.

About Concord Medical

Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information, please see http://ir.ccm.cn.

About Concord Healthcare

Concord Healthcare is an oncology healthcare provider in China. Concord Healthcare serves both cancer patients through self-owned medical institutions and third-party medical institutions through medical equipment, software and related services. In its self-owned medical institutions, Concord Healthcare provides a full spectrum of oncology healthcare services to cancer patients across the entire care continuum, leveraging its multidisciplinary team specialists and diagnosis and treatment capabilities featuring precision radiation therapy. Through its medical equipment, software and related services, Concord Healthcare serves a widespread network of enterprise customers, primarily hospitals, with integrated oncology-related services, including primarily sales and installing of medical equipment and software, management and technical support, and operating lease.

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

View original content:https://www.prnewswire.com/news-releases/concord-medical-regains-compliance-with-nyse-minimum-price-requirement-302216531.html

SOURCE Concord Medical Services Holdings Limited

FAQ

What compliance issue did Concord Medical (CCM) resolve with the NYSE on August 6, 2024?

Concord Medical (CCM) regained compliance with the NYSE's minimum price requirement, which mandates a minimum average share price of US$1.00 over a 30 trading-day period.

When was Concord Medical (CCM) initially notified of non-compliance with NYSE listing standards?

Concord Medical (CCM) was initially notified of non-compliance with NYSE listing standards due to its trading price on February 12, 2024.

What is the NYSE Minimum Price Requirement that Concord Medical (CCM) has met?

The NYSE Minimum Price Requirement is a continued listing criterion that requires a minimum average share price of US$1.00 over a 30 trading-day period.

How has regaining compliance affected Concord Medical's (CCM) listing status on the NYSE?

By regaining compliance, Concord Medical (CCM) is no longer considered below the NYSE Minimum Price Requirement and has secured its continued listing on the New York Stock Exchange.